1. Home
  2. ANL vs BVS Comparison

ANL vs BVS Comparison

Compare ANL & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Logo Bioventus Inc.

BVS

Bioventus Inc.

N/A

Current Price

$10.88

Market Cap

910.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANL
BVS
Founded
2004
2011
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
910.2M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
ANL
BVS
Price
$10.80
$10.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
★ $29.50
$16.60
AVG Volume (30 Days)
268.1K
★ 606.9K
Earning Date
08-14-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 163.46
EPS
N/A
★ 0.60
Revenue
N/A
★ $568,087,000.00
Revenue This Year
$243.83
$4.72
Revenue Next Year
N/A
$6.41
P/E Ratio
★ N/A
$18.12
Revenue Growth
★ N/A
N/A
52 Week Low
$0.88
$6.47
52 Week High
$17.25
$15.89

Technical Indicators

Market Signals
Indicator
ANL
BVS
Relative Strength Index (RSI) 46.74 33.79
Support Level $8.95 $8.21
Resistance Level $11.90 $11.00
Average True Range (ATR) 0.99 0.66
MACD 0.25 -0.24
Stochastic Oscillator 72.55 15.20

Price Performance

Historical Comparison
ANL
BVS

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

Share on Social Networks: